Victor Corrigan, MD
Cardiovascular Disease · Atlanta, GANPI 1740289446
Payments from drug & device makers
What this record shows
This record is dominated by other: $108,611 of the $113,907 with a category attached, or 95.4%. Edwards Lifesciences accounts for 95.4% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2024 at $108,008 and has fallen 97.7% since, to $2,454 in 2025. Among cardiovascular disease clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 260 payments — averaging $438.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$109K
- Novartis$1K
- Johnson & Johnson$1K
- Amgen$370
- Pfizer$346
- Boston Scientific$326
- plus $2K from 24 others
What the payments were for
- Food & beverage$5,2835%
- Education$130%
- Other$108,61195%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 2 | $108,611 |
| Novartis | 62 | $1,040 |
| Johnson & Johnson | 57 | $1,034 |
| Amgen | 19 | $370 |
| Pfizer | 16 | $346 |
| Boston Scientific | 7 | $326 |
| AstraZeneca | 14 | $318 |
| Cvrx, Inc. | 2 | $240 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $222 |
| Boehringer Ingelheim | 13 | $202 |
| E.r. Squibb & Sons, L.L.C. | 10 | $190 |
| Merck | 9 | $155 |
| Amarin Pharma, Inc. | 7 | $135 |
| Heartflow, Inc. | 5 | $97 |
| Medtronic | 2 | $91 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $62 |
| Kiniksa Pharmaceuticals, Ltd. | 4 | $62 |
| Nuwellis, Inc. | 2 | $51 |
| Sanofi-aventis U.S. LLC | 3 | $50 |
| Actelion Pharmaceuticals US, Inc. | 2 | $50 |
| Esperion Therapeutics, Inc. | 3 | $45 |
| Bayer | 2 | $40 |
| Saranas, Inc. | 1 | $35 |
| Angiodynamics, Inc. | 1 | $31 |
| Cardiovascular Systems Inc. | 1 | $23 |
| Abiomed | 1 | $19 |
| Spectrawave, Inc | 1 | $19 |
| Baxter Healthcare | 1 | $16 |
| Abbott | 1 | $15 |
| Chiesi USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Barostim Neo System$214
- SYNERGY$159
How this compares
$113,907 in reported general payments places this provider in the 95th percentile of 640 cardiovascular disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 206 | $239,449 |
| XareltoRivaroxaban | 74 | $77,984 |
| EntrestoSacubitril/Valsartan | 42 | $53,324 |
| FarxigaDapagliflozin Propanediol | 13 | $19,061 |
| JardianceEmpagliflozin | 18 | $18,779 |
| Metoprolol Succinate | 343 | $3,612 |
| Rosuvastatin Calcium | 215 | $3,562 |
| Atorvastatin Calcium | 384 | $3,391 |
| Amlodipine Besylate | 277 | $1,673 |
| Ezetimibe | 78 | $1,449 |
| Carvedilol | 160 | $1,258 |
| Potassium Chloride | 38 | $1,242 |
| ClopidogrelClopidogrel Bisulfate | 89 | $1,238 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 83 | $1,038 |
| Furosemide | 170 | $1,002 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $346 | $239,449206 claims |
| Johnson & JohnsonXarelto | $1,034 | $77,98474 claims |
| NovartisEntresto | $1,040 | $53,32442 claims |
| AstraZenecaFarxiga | $318 | $19,06113 claims |
| Boehringer IngelheimJardiance | $202 | $18,77918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 640 cardiovascular disease providers in Georgia.
Other cardiovascular disease in Atlanta
- Joseph MillerAtlanta$573K
- Utpal PandyaAtlanta$221K
- Randolph MartinAtlanta$177K
- Mani VannanAtlanta$157K
- Elizabeth OfiliAtlanta$107K
- Isida BykuAtlanta$78K
- Cindy GrinesAtlanta$75K
- Anekwe OnwuanyiAtlanta$56K
- Melvin EcholsAtlanta$51K
- Venkateshwar PolsaniAtlanta$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.